Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | GLUL | P15104 | 1/20 | 0.44 |
| ▸ | GCLC | P48506 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13892954 | 0.81 | PTGS1 (0.48) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL19697646 | 0.81 | PTGS1 (0.48) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL8967238 | 0.80 | GLUL (0.52) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL195643 | 0.80 | GLUL (0.52) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL1980143 | 0.80 | GLUL (0.52) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL23649439 | 0.78 | GLUL (0.50) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL28229605 | 0.78 | GLUL (0.50) | PTGS1SLC7A11GLULGCLC | |
| SCHEMBL3348054 | 0.77 | GLUL (0.60) | GLULGCLCGRM8GRM6GRM7 | |
| Serine SCHEMBL9167560 | 0.76 | PTGS1 (0.48) | PTGS1SLC7A11GLULGRM8GRM6 | |
| SCHEMBL5054658 | 0.76 | PTGS1 (0.43) | PTGS1SLC7A11GLULGCLCGRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002469-A2 | THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| US-6939854-B2 | Peptide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6846806-B2 | Peptide inhibitors of Hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1252178-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | PTGS1 118/4885SLC7A11 2028/4885GLUL 3684/4885 |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | PTGS1 620/4885SLC7A11 1649/4885GLUL 1420/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | PTGS1 757/4885SLC7A11 2522/4885GLUL 1771/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | PTGS1 944/4885SLC7A11 2660/4885GLUL 1997/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | PTGS1 433/4885SLC7A11 3317/4885GLUL 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.